OncLiveDr. Wagstaff on the Survival Benefit of Immunotherapy in Bladder CancerOncLiveJohn Wagstaff, MD, professor at Swansea University Medical School, discusses the survival benefit of immunotherapy for patients with bladder cancer. Most of the trials… Continue reading
|
Immunotherapy Toxicity Management in NSCLC
OncLive Everett Vokes, MD: Briefly, Roy, can you comment on toxicities with checkpoint inhibitors? What are toxicities community oncologists should know? Roy Herbst, MD, PhD: Right. And that’s the reason why we really want to make sure we have some efficacy. |
|
Next Steps in Research for Immunotherapy for HNSCC
OncLive So, I think that there’s going to be a lot of room for looking at combinations of existing therapies, whether they’re conventional DNA damage approaches or they’re targeted therapies with immunotherapy. I would encourage the people who are watching … |
|
Poseida’s CAR T-cell Therapy Eradicates Previously Incurable Prostate Cancer in Mice
Prostate Cancer News Today Poseida Therapeutics’ CAR T-cell therapy P-PSMA-101 eradicated a previously incurable type of human prostate cancer implanted in mice, the company reported. Another CAR T-cell therapy that has reached doctor’s offices has failed to counter the cancer, … |